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SUMMARY 
Background. Primary measures for preventing morbidity and mortality associated with bleeding 
gastroesophageal varices in cirrhotic patients include endoscopic screening.  
Aims. Among cirrhotic hepatitis C virus (HCV) patients attending specialist care in Scotland, to 
identify factors associated with (i) screening and (ii) a first hospital admission for variceal 
bleeding. 
Methods. The Scottish Hepatitis C Clinical Database was linked to national hospitalisation and 
deaths records to identify all chronic HCV patients diagnosed with cirrhosis in 2005–2016 
(n=2741). The adjusted odds of being screened by calendar year period were estimated using 
logistic regression, and the adjusted hazard ratio (HR) of a first variceal bleed using Cox 
regression. 
Results. 34% was screened within 12 months before/after cirrhosis diagnosis. The proportion 
screened was stable in 2005–2010 at 42%, declining to 37% in 2011–2013 and 26% in 2014–2016. 
Odds of screening were decreased for age-groups <40 (OR=0.61, 95% CI:0.48–0.77) and 60+ years 
(OR=0.67, 95% CI:0.48–0.94), history of antiviral therapy (OR=0.70, 95% CI:0.55–0.89), and 
cirrhosis diagnosis in 2014–2015, compared with 2008–2010 (OR=0.67, 95% CI:0.52–0.86). 
Compared with 2008–2010, there was no evidence for an increased/decreased relative risk of a 
first variceal bleed in any other period, but viral clearance was associated with a lower risk 
(HR=0.56, 95% CI:0.32-0.97). 
Conclusions. Overall screening uptake following cirrhosis diagnosis was low, and the decline 
into the IFN-free therapy era is of concern. The stable bleeding risk over time may be attributable 
both to ongoing prevention initiatives and to changing diagnostic procedures creating a patient 
pool with milder disease in more recent years. 
 
KEYWORDS 
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INTRODUCTION 
Portal hypertension, as a consequence of progressive liver disease caused by chronic infection 
with the hepatitis C virus (HCV), can give rise to severe complications such as bleeding 
gastroesophageal varices. Variceal haemorrhage can be life-threatening, and even if treated 
carries an estimated mortality risk of 15–20% within six weeks following the first bleed.1-3 
 
Screening of cirrhotic patients with HCV infection for varices by endoscopy is an established 
strategy for identifying patients at-risk for variceal bleeding. Guidelines for screening followed by 
appropriate pharmacological or other prevention measures have long been available.4,14 However, 
there have been very few national-level studies investigating real-world adherence to screening 
guidelines,5 or reporting rates of variceal bleeding over time among populations of individuals 
with chronic HCV infection. 
 
The monitoring of temporal trends in the occurrence of variceal bleeding has perhaps gained in 
importance with the scaled-up deployment of the new generation of interferon-free (IFN-free) 
antiviral therapies for chronic HCV infection, increasing the number of treated patients with 
cirrhosis achieving a sustained virologic response (SVR). In Scotland and elsewhere, these drugs 
show great promise for reducing the rising HCV-related liver disease burden, including a 
decreased progression from compensated to decompensated cirrhosis (DC).6 Nevertheless, 
vigilance to variceal screening should not be relaxed, as one impact of a scale-up in IFN-free 
treatment will be an increasing number of HCV patients living with cirrhosis. 
 
UK guidelines recommend endoscopic screening in all patients with cirrhosis,7 and practice at 
most Scottish specialist liver clinics is to schedule a first endoscopy once diagnosis of cirrhosis 
made. Screening recommendations were recently fine-tuned at the most recent Baveno VI 
consensus conference and published in September 201514, with the aim to identify compensated 
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cirrhosis patients at very low risk for variceal bleeding; such patients could be excluded from 
endoscopic screening if they had liver stiffness by transient elastography <20 kPa and a platelet 
count >150,000/mm3. Given the long-standing availability of guidelines for screening of cirrhotic 
patients, it is of interest to know if there has been an impact on variceal bleeding rates from 
endoscopic screening over the last decade. As this question cannot be addressed directly from 
observational data, we formulated the following study objectives: (i) describe the uptake of 
endoscopic screening over time amongst HCV-infected cirrhotic patients with no known history 
of variceal bleeding, and investigate the factors associated with screening uptake in this patient 
population; (ii) describe the frequency and rates of a first variceal bleeding episode in the same 
population over the same period, and assess the factors associated with the risk of a first bleed. 
We anticipated that screening practice may have led to improvements in bleeding rates over our 
study period. A specific aim under both objectives was to investigate any difference in outcome 
comparing pre-IFN-free (before 2014) and IFN-free (from 2014 onwards) treatment eras. 
 
METHODS 
All analyses 
Data sources. The Scottish Hepatitis C Clinical Database is a comprehensive record of all HCV 
patients attending specialist tertiary care and represents 17 out of 18 specialist clinics across 
Scotland.8 This database encodes detailed clinical and epidemiological information on patients 
attending a specialist clinic for care/management of HCV infection; informed 'opt-out' consent 
was obtained for use of their data. The HCV Clinical Database was electronically linked to the 
national deaths registry and the Scottish Morbidity records (SMR01; a database holding all acute 
inpatient and daycase hospital episodes held by Information Services Division (ISD)) by ISD 
using probabilistic methods.9 The resulting linkage was anonymised before analysis. 
 
Study population and setting. The study population consisted of all patients with chronic HCV 
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infection on the Scottish Hepatitis C Clinical Database diagnosed with cirrhosis between 1 
January 2005 and 31 December 2016, with no history of variceal bleeding (according to 
information held on this database), and who had been diagnosed with cirrhosis no earlier than 
one year prior to their first attendance at one of Scotland’s specialist liver clinics (to ensure 
continuity of clinical care for potential referral for endoscopy). In our study population, cirrhosis 
was diagnosed via a combination of biopsy, transient elastography (FibroScan®), abdominal 
ultrasound, clinical examination, and routine liver function tests. We estimated the annual 
proportion of all cirrhosis diagnoses that were made using transient elastography by matching 
the cirrhosis diagnosis date for each patient to dates of diagnostic procedures held in a separate 
table. 
 
The eligible study population for the descriptive analysis and analysis of bleeding risk (see below) 
was larger than for the analysis of screening uptake; the former were diagnosed with cirrhosis 
within the period 2005–2016, which we term the 'entire period' study population, and the latter in 
2005–2015 (to allow 12 months for endoscopic screening following diagnosis). 
 
Endoscopic screening was determined via the procedure code fields in SMR01;  we assumed the 
presence of one or more of this procedure code set indicated screening endoscopy. Both non-
bleeding and bleeding oesophageal varices episodes were identified via the presence of discharge 
diagnoses codes (using International Classification of Disease (ICD10); see Supporting 
Information, Table S1) in the same data source. These codes have been used extensively in 
previous research by ourselves and others.10,11 Note that discharge diagnoses are entered for day-
cases as well as for inpatient admissions.  The record-linkage also provided date of death, 
required for censoring. 
 
Descriptive analysis. We plotted the number of persons screened and the number of first bleeds 
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among the 'entire period' study population, by year of event. Rates of first variceal bleed over 
calendar year period were computed using person-time-methods (i.e., events divided by person-
time at risk).  
 
Uptake of variceal screening 
Regression analysis. Logistic regression analysis was conducted on the '2005-2015' study 
population to estimate the association between first endoscopic screening within 12 months prior 
to or subsequent to date of cirrhosis diagnosis and period of diagnosis (2005-2007, 2008-2010, 
2011-2013, 2014-2015; multiple periods allow potential trends to be observed, with 2008-2010 
logically selected as reference category), adjusting for a number of covariates. To allow a 
minimum of 12 months to observe an endoscopic procedure following cirrhosis diagnosis, 
analysis was restricted to cirrhosis diagnoses made before or on 31 December 2015; hence the 
total and number of patients per covariate level differ between Tables 1 and 2. Covariates of 
interest included sex, age-group at diagnosis (<40, 40-49, 50-59, 60+ years), ethnicity (white, non-
white), risk group (people who inject drugs [PWID], non-PWID/not known; combined post-hoc 
on basis of similar estimated coefficients), historical alcohol use (self-reported: >50 units per week, 
≤50 units per week/not known), initiation on antiviral treatment at baseline (ie. prior to cirrhosis 
diagnosis date), the presence of ascites and encephalopathy at baseline (according to information 
on the Clinical Database), and mode of cirrhosis diagnosis: radiology (which includes ultrasound 
and FibroScan®), clinical examination, or other/not known (which includes biopsy). 
 
Sensitivity analyses. We also investigated the association between period of cirrhosis diagnosis and 
variceal screening among three subgroups of the study population: (a) patients likely to have 
more advanced disease (defined as the presence of ascites at baseline); (b) patients inferred to 
have been diagnosed with cirrhosis using FibroScan® (i.e., more likely to have early, less 
advanced cirrhosis); and (c) patients not known to have been diagnosed using FibroScan®. To 
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address possible increasing use of Baveno VI criteria to exclude very low-risk patients from 
screening, we additionally investigated – among the subgroup of patients with available platelets 
counts – the association between period of cirrhosis diagnosis and the odds of endoscopy among 
patients under and over the platelet count threshold (150k/mm3 , Baveno VI14 )  
 
First admission for bleeding varices following cirrhosis diagnosis 
Regression analysis. Cox proportional-hazards regression analysis was conducted to estimate the 
adjusted hazard ratio of a first variceal haemorrhage according to calendar year period (2005-2007, 
2008-2010, 2011-2013, 2014-2016). Covariates considered were: sex, age-group, ethnicity (white, 
non-white), risk group (PWID, non-PWID/not known), historical alcohol use (self-reported: >50 
units per week, ≤50 units per week/not known), initiation on/outcome of antiviral therapy 
(never treated, non-SVR, or SVR), first ascites occurrence, first encephalopathy occurrence, and 
mode of cirrhosis diagnosis (radiology/ultrasound/FibroScan®, clinical examination, or 
other/not known). Age, antiviral treatment, ascites, and encephalopathy were all specified as 
time-dependent (also known as time-updated) covariates. Follow-up was defined to begin on the 
date of cirrhosis diagnosis and to end at the earliest of first bleed, death, or 31 December 2016. 
The inclusion of covariates in the multifactorial model was determined by a (pre-specified) P≤0.25 
obtained in univariate analysis. The Cox proportional hazards assumption was confirmed 
graphicallyusing Schoenfeld residuals. 
 
All statistical analyses were conducted in the R statistical programming environment, version 
3.0.3.12 
 
Estimation of sensitivity of endoscopic procedure codes 
To determine the sensitivity of the SMR01 codeset used to define an inpatient/daycase hospital 
admission for endoscopic screening, we carried out a validation study using data on endoscopic 
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procedures in the HCV Clinical Database held by a single clinic, Glasgow Royal Infirmary (GRI). 
Data on the HCV Clinical Database were considered as the gold standard (with GRI taken as a 
representative sample) and the overlap in individual patients who had undergone a non-
interventional endoscopic procedure according to each data source could be determined. 
 
RESULTS 
Variceal screening among cirrhotic patients 
The 'entire period' study population consisted of a total of 2741 patients diagnosed with cirrhosis 
between 1 January 2005 and 31 December 2016, of whom 46% (1272/2741) had undergone 
endoscopic screening (determined using procedure codes) by 31 December 2016. 249 (9.1%) 
patients died without ever being screened, with a median time to death of 1.62 years. Nine of 
these deaths had variceal bleeding as an underlying/contributing cause of death. The annual 
number of patients with a first diagnosis of cirrhosis rose steadily from 83 in 2005 to 387 in 2016. 
The annual proportion of all diagnoses estimated to be based on transient elastography also rose 
rapidly over the study period, to a high of 69% in 2014 (Supporting Information, Table S3). The 
annual number screened increased from 25 (in 2005) to 170 (in 2013), and then declined to 130 in 
2016 (Fig. 1). The most frequently occurring endoscopic procedure code was G45.9 ('Unspecified 
diagnostic fibreoptic endoscopic examination of upper gastrointestinal tract'), accounting for 73% 
of screening records. Three hundred and thirty-two endoscoped patients died  (5% with variceal 
bleeding as an underlying/contributing cause) before the end of follow-up. 
 
Table 1 compares the patient characteristics between patients screened within +/- 12 months of 
cirrhosis diagnosis and patients not screened by 31 December 2016. There were proportionally 
more screened patients amongst those ever initiated on antiviral therapy, compared with never 
initiated (35% vs. 27%; P<0.001), and amongst patients with non-white compared with white 
ethnicity (43% vs. 32%; P=0.014). Of the screened patients, 6.8% (63/927) had undergone 
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endoscopic investigation in the 6–12 month period preceding cirrhosis diagnosis, and 12.6% 
(117/927) within the six months preceding diagnosis. The median time interval between date of 
cirrhosis diagnosis and endoscopy amongst the 747 patients screened after diagnosis was 177 
days (interquartile range: 77–492 days).  
 
Over the entire study period, 1631 patients were ever initiated on IFN-containing or IFN-free 
antiviral therapy, of whom 813 had a start date of treatment on or subsequent to 9 June 2014 (i.e., 
the date sofosbuvir approved by Scottish Medicines Consortium13). The difference in the 
proportions of patients screened according to baseline history of antiviral therapy also varied 
between pre-IFN-free (2005-2013) and IFN-free (2014-2016) therapy eras. In the pre-IFN-free era, 
54% vs 58% (treated vs. not treated at baseline) were endoscopically screened, compared with 22% 
vs. 31% (treated vs. not treated) in the IFN-free era (Supporting Information, Table S2). 
 
Among the '2005-2015' study population, 37% (876/2354) were endoscoped within the 12 months 
preceding or following cirrhosis diagnosis date (Table 2). Multifactorial logistic regression 
indicated a significantly decreased odds of being screened for persons aged <40 years (OR=0.61, 
95% CI: 0.48–0.77) and aged 60+ years (OR=0.67, 95% CI: 0.48–0.94) at time of diagnosis 
(compared with the reference age-group 40-49 years), patients with historical alcohol 
consumption of ≤50 units per week/not known (OR=0.75, 95% CI: 0.63–0.90) compared with >50 
units/week, patients previously initiated on antiviral therapy (OR=0.70, 95% CI: 0.55–0.89), mode 
of cirrhosis diagnosis of 'other/NK' (OR=0.69, 95% CI: 0.52–0.90) compared with radiology, and 
cirrhosis diagnosis in 2014-2015 compared with 2008-2010 (OR=0.67, 95% CI: 0.52–0.86). 
 
Sensitivity analyses. Comparable multifactorial logistic regression analyses conducted for 
specific subgroups as sensitivity analysis (Supporting Information, Table S4) indicated that for 
patients with more advanced disease (i.e., ascites) at baseline and for those patients not known to 
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have been diagnosed using transient elastography, the adjusted odds of screening were lower for 
cirrhosis diagnoses made in 2014-2015 compared with 2008-2010 (OR=0.34, 95% CI: 0.14-0.84 and 
OR=0.62, 95% CI:0.43-0.90, respectively). 
 
Sixty-two percent of the '2005-2015' study population had a platelets test result around the time of 
cirrhosis diagnosis. There was a strong correlation (Pearson r=0.94) between year of cirrhosis 
diagnosis and median platelet count for these patients. The adjusted ORs of screening associated 
with period of diagnosis among both patient subgroups (i.e., with platelet count ≤150k/mm3 
and  >150k/mm3) tended to decline with period (Supporting Information, Table S5), but the odds 
of screening in the later periods are not statistically significantly lower than for the reference 
period, and there was no indication of a stronger reduction in the odds of screening for 
the >150k/mm3 subgroup. 
 
First admission for bleeding varices following cirrhosis diagnosis 
Among the 'entire period' study population, a total of 88 cirrhotic patients had a first bleed 
between date of cirrhosis diagnosis and 31 December 2016. Fifty-two percent (46/88) of these 
patients subsequently died, prior to 31 December 2016. Twenty-two (0.8%) patients died without 
a first hospital admission for variceal bleeding. The two most frequent underlying causes of death 
codes for these 22 patients were: R99 (other ill-defined and unspecified causes of mortality [6/22] and 
X42 (accidental poisoning by and exposure to narcotics and psychodysleptics [5/22]). 
 
The annual number of patients with first bleeds reached a peak of 20 in 2015, followed by a drop 
to 11 in 2016 (Fig. 1). Unadjusted variceal bleeding rates declined from the first (2005-2007) to the 
third (2011-2013) triennium of the study period (Table 3), but the Cox regression analysis 
indicated no evidence for differing hazard ratios for bleeding in any triennium compared with 
the reference period 2008-2010. A higher hazard of bleeding was associated with the presence of 
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ascites only (HR=2.95, 95% CI: 1.79–4.86), and there was a lower hazard of bleeding associated 
with achievement of SVR (HR=0.56, 95% CI: 0.32-0.97). 
 
Validation of the endoscopic procedure codeset 
Taking the data on the HCV Clinical Database to be the gold standard, 113 GRI patients 
underwent an endoscopic procedure in 2005-2016, of whom 107 also had a relevant procedure 
indicated on SMR01. 
 
DISCUSSION 
In our national-level study population of 2,741 patients with chronic HCV infection and cirrhosis, 
we found that despite a steep rise in the cumulative number of cirrhotic patients over the study 
period, the annual number of first hospital admissions for variceal bleeding increased only 
slightly over the same period. Although the number of endoscopically screened patients 
increased steadily over time (Fig. 1), the uptake of variceal screening was consistently low (34% 
within the 12 months preceding or following diagnosis), and there was a significant drop in the 
odds of screening in the IFN-free era (2014-2015) compared with the reference period, even once 
relevant patient characteristics and other confounders were adjusted for. This finding held up in 
comparable analyses of subgroups of patients deemed less likely to have mild disease 
(Supporting Information, Table S4). 
 
The low odds of endoscopic screening associated with antiviral treatment (adjusted odds ratio of 
0.67) – despite current recommendations to screen following cirrhosis diagnosis – is notable, and 
may partly reflect patients’ unwillingness to undergo an invasive procedure upon achieving SVR. 
In addition, many patients with FibroScan® scores in the low cirrhotic range upon diagnosis may 
normalize sufficiently post-treatment such that the risk of bleeding becomes low enough that 
screening is no longer warranted, when their FibroScan readings are no longer in the cirrhotic 
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range and their platelet counts are >150k/mm3 (A. Fraser, pers. comm.). 
 
We observed a downward trend in the rate of admission with a first variceal bleed over time 
(Table 3); however, after adjustment for patient factors, antiviral treatment/outcome and the 
occurrence of other decompensation events, there was no evidence for a statistically significant 
drop in the hazard ratio for bleeding in either of the two most recent triennia (2011-2013, 2014-
2016), compared with the reference triennium 2008-2010. Our study could not elucidate the cause 
of the apparent decline in bleeding rates over time, because we lacked data on primary 
prophylaxis administered to either screened or non-screened patients. In addition, we could not 
directly compare rates of first admission with bleeding varices between screened and non-
screened patients, because we did not have information of what kind of primary prophylaxis (if 
any) had been administered to patients in each group. 
 
Because the observed declining trend in the rate of a first variceal bleed over triennium reached a 
stable (low) point in 2011-2013 of 7.1/1,000 person-years, this finding might be attributed to the 
introduction of IFN-free therapies, which – through widespread treatment of cirrhotic patients 
beginning in 2014 – has been shown to be associated with a reduction in new cases of hepatic 
decompensation.6 At the individual patient level, achieving an SVR was associated with a greatly 
reduced risk (adjusted HR of 0.56) of a first variceal bleed. However, IFN-free therapies cannot 
explain the low variceal bleeding rate observed prior to 2014; thus, it remains unclear whether 
this currently low rate is related to diagnosis of earlier stage cirrhosis, effective endoscopic 
screening, pharmacological prophylaxis, or other factors. 
 
Screening rates in our cohort concur with findings of a large study using the US Veterans Health 
Administration database,5 in which 34% of HCV-infected patients with cirrhosis were 
endoscopically screened per AASLD guidelines within the 1 year preceding or 1 year following 
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cirrhosis diagnosis. In our study, 34% of patients diagnosed with cirrhosis 2005-2016 had been 
screened within the 1 year preceding or following diagnosis.  
 
Strengths of our study are good internal validity; high database coverage (17/18 specialist clinics) 
means that almost all cirrhotic patients in tertiary care were included. However, because 
attendance at a clinic would normally be a prerequisite for diagnosis of cirrhosis and variceal 
screening, our results cannot be generalised to HCV-infected persons with (largely asymptomatic) 
cirrhosis not attending specialist care. 
 
The principal reason that a patient may not be referred for endoscopic screening, which our study 
was unable to address, is the possible substitution of non-selective beta-blockers without 
(invasive) endoscopy. We necessarily assumed 100% eligibility – all cirrhotic patients – for 
endoscopic screening, ignoring other, possibly unmeasured, clinical factors such as co-
morbidities that might make a patient ineligible. As well, achievement of viral clearance through 
antiviral therapy may influence the likelihood of screening; we attempted to adjust for this 
through inclusion of a covariate for history of antiviral treatment in the logistic regression 
analysis, and we observed a reduced odds of screening among the subset of patients who had 
previously been initiated on treatment. A further factor that may underlie the drop in screening 
uptake in the IFN-free treatment era, which we could not measure, is a potential change in 
referral practice. Because of better tolerability of the new regimens, many patients are now being 
treated by an infectious disease specialist whereas they previously would have been referred to a 
gastroenterologist or hepatologist (who may be more inclined to screen for varices). However, 
recent changes in variceal screening guidelines14 that recommend the use of non-invasive markers 
to identify patients at very low risk of developing bleeding varices are unlikely to have 
influenced practice across our analysis timeframe, with the possible exception of the final year of 
our study period. The sensitivity analysis among the patient subgroup with available platelets 
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counts also did not suggest increasing application of Baveno VI criteria, but was consistent with a 
trend in the frequency of diagnosis of less advanced disease over time. As the use of criteria 
based on non-invasive markers becomes more widespread to spare unnecessary endoscopies, 
even lower screening uptake may be observed in future, and monitoring of uptake will need to 
take factors such as antiviral treatment into consideration.16,17 
 
The origin of the apparent downward trend in bleeding rates between 2005 and 2011-2013 is 
multifactorial; possible reasons include – among others – diagnosis of cirrhosis made in patients 
with milder disease (due to increasing use of transient elastography; Supporting Information, 
Table S3) in more recent years, more effective screening for varices, and slowing of 
decompensation due to improved clinical care,. In addition, we could only crudely adjust for 
severity of liver disease in the regression analysis, as we lacked data on prognostic factors such as 
the Child-Pugh score or the hepatic venous pressure gradient as a measure of clinically 
significant portal hypertension.15 A possible influential factor (which could not be addressed in 
the current study) may be the changes in recommendations for pharmacological treatment as 
primary prophylaxis against variceal bleeding.7 Historically propranolol was used in Scotland, 
but around 2008 many clinicians transitioned to carvedilol, which has superior portal 
haemodynamic effects in cirrhosis.  
 
A further limitation is our assumption that all gastroesophageal endoscopic examinations were 
carried out for variceal screening purposes; we could not distinguish other reasons for the 
procedure using our linked dataset. Nineteen percent (180/927) of our cirrhotic patient pool had 
a date of cirrhosis diagnosis up to 12 months following endoscopic examination. For some of 
these patients, the clinician may have made a cirrhosis diagnosis upon viewing the endoscopy 
results, but this may have not been recorded in the database until much later. Finally, incomplete 
data on the HCV Clinical Database regarding patients’ historical alcohol intake and the 
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occurrence of decompensation events, as well as record-linkage errors between this database and 
SMR01, may have lead to biased estimation of effect measures in either regression analysis. 
 
Conclusions. Uptake of variceal screening following cirrhosis diagnosis among Scotland’s chronic 
HCV-infected population has been historically low, and the observed decline into the era of IFN-
free therapy is a potential cause for concern. This decline does not appear to be attributable to 
patients being diagnosed at an earlier stage of cirrhosis over the study period (i.e., possibly due to 
increasingly frequent use of transient elastography), as a significant drop in uptake in 2014-2016 
was also observed in sensitivity analyses of subgroups of patients with ascites at baseline and 
patients not known to have been diagnosed using transient elastography. As HCV treatment 
becomes more devolved from hospital-based to community-based (primary care and other non-
specialists), there is at risk that patients – often from harder to reach populations – needing 
variceal screening may not be identified, or be less responsive to engaging with screening. 
Because the annual number of first admissions for bleeding varices was relatively constant over 
time, despite a steep rise in new cirrhosis diagnoses, our analysis suggests that active prevention 
initiatives – including effective variceal screening – may have contributed to this observation, but 
changing diagnostic procedures over the study period resulting in diagnosis of cirrhosis at earlier, 
even asymptomatic, stages, could also underlie the stable numbers of annual admissions and lack 
of changing risk of bleeding over time. The halved risk of bleeding associated with antiviral 
therapy-induced viral clearance (hazard ratio of 0.56) is reassuring and counteracts the 
potentially negative impact of a lower screening uptake in an era in which patients with 
compensated cirrhosis can be safely and effectively treated. 
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Table 1. Baseline characteristics of the cirrhotic chronic HCV-infected study population (N=2741), 
comparing patients who were not endoscopically screened for varices within +/- 12 months of 
date of cirrhosis diagnosis and those who were screened.  
   
 Not screened Screened  
Variable N   (col %) N  (col%) Row %  P-value 
 
Total 1814 (-) 927 (-) 33.8% 
 
Female 446 (24.6) 241 (26.0) 35.1% 0.45 
Male 1386 (75.4) 686 (74.0) 33.4% 
 
Age at cirrhosis    <0.001 
 <40 394 (21.7) 145 (15.6) 26.9% 
 40-49 732 (40.4) 444 (47.9) 37.8% 
 50-59 506 (27.9) 256 (27.6) 33.6% 
 60+ 182 (10.0) 82 (8.8) 31.1%     
 
Ethnicity group    0.014 
 Non-white 93 (5.1) 70 (7.6) 42.9% 
 White 1721 (94.9) 857 (92.4) 32.3% 
 
Risk group    0.34 
 Non-PWID/NK 634 (35.0) 363 (39.2) 36.4%  
 PWID 1180 (65.0) 564 (60.8) 32.3%    
 
Alcohol use history    <0.001 
 >50 units/wk 636 (35.1) 416 (44.9) 39.5% 
 ≤50 units/wk or NK 1178 (64.9) 511 (55.1)  30.3% 
 
Period of cirrhosis diagnosis   <0.001 
 2005-2007 153 (8.4) 114 (12.3) 42.7% 
 2008-2010 286 (15.8) 203 (21.9) 41.5% 
 2011-2013 583 (32.1) 336 (36.2) 36.6% 
 2014-2016 792 (43.7) 274 (29.6) 25.7% 
 
Initiated on antiviral therapy at baseline  <0.01 
 No 1488 (82.0) 806 (86.9) 35.1% 
 Yes  326 (18.0) 121 (13.1) 27.1% 
 
Ascites at baseline    0.021 
 No 1656 (91.3) 820 (88.5) 33.1%  
 Yes 158 (8.7) 107 (11.5) 40.4%     
 
Encephalopathy at baseline   <0.001 
 No 1673 (92.2) 911 (98.3) 35.3%  
 Yes 141 (7.8) 16 (1.7) 10.2% 
 
Mode of cirrhosis diagnosis   <0.001 
 Radiology† 1377 (75.9) 762 (82.2) 35.6% 
 Clinical exam. 205 (11.3) 62 (6.7) 23.2% 
 Other/NK† 232 (12.8) 103 (11.1) 30.7% 
 
 
Note. PWID=people who inject drugs; NK=not known. P-values from chi-squared test 
comparing frequency distributions between screened and not screened patients. 
†Radiology includes ultrasound and Fibroscan. Other/NK includes biopsy (25%), LFTs and 
platelets (20%), hyaluronic acid (39%), endoscopy (11%), and NK (5%).  
20
Table 2. Results of logistic regression analysis of the odds of variceal screening within +/- 12 
months of cirrhosis diagnosis; the study population is defined as patients with date of cirrhosis 
diagnosis between 1 January 2005 and 31 December 2015 (N=2354). 
 
  Unadjusted Adjusted  
Covariate n OR  (95% CI) OR  (95% CI) 
 
(All) 876 -  - 
 
Male 650  Ref.  Ref 
Female 226 1.07 (0.88-1.29) 1.09 (0.90-1.34)    
 
Age 
 <40 143 0.65 (0.51-0.82) 0.61 (0.48-0.77) 
 40-49 421 Ref.  Ref. 
 50-59 240 0.83 (0.68-1.01) 0.82 (0.67-1.01) 
 60+ 72 0.70 (0.51-0.95) 0.67 (0.48-0.94) 
 
Ethnicity group 
 Non-white 65 1.36 (0.97-1.91) 1.38 (0.96-1.99) 
 White 811 Ref.  Ref. 
 
Risk group 
 Non-PWID/NK 341 1.13 (0.95-1.35) 1.19 (0.98-1.45) 
 PWID 535 Ref.  Ref. 
 
Alcohol use history 
 >50 units/wk 390 Ref.  Ref. 
 ≤50 units/wk 486 0.73 (0.62-0.87) 0.75 (0.63-0.90) 
   or NK 
 
Period of cirrhosis diagnosis 
 2005-2007 114 1.05 (0.78-1.42) 1.06 (0.78-1.46) 
 2008-2010 203 Ref.  Ref. 
 2011-2013 336 0.81 (0.65-1.02) 0.80 (0.63-1.01) 
 2014-2015 223 0.69 (0.54-0.88) 0.67 (0.52-0.86) 
 
Initiated on antiviral therapy (at baseline) 
 No 760 Ref.  Ref. 
 Yes 116 0.68 (0.54-0.86) 0.70 (0.55-0.89) 
 
Ascites 
 No 820 Ref.  Ref. 
 Yes 107 1.38 (1.04-1.82) 1.27 (0.92-1.75) 
 
Encephalopathy 
 No 911 Ref. Ref. 
 Yes 16 0.57 (0.30-1.08) 0.57 (0.28-1.19) 
 
Mode of cirrhosis diagnosis 
 Radiology† 718 Ref.  Ref. 
 Clinical exam. 57 0.95 (0.67-1.33) 0.88 (0.58-1.34) 
 Other/NK† 101 0.78 (0.60-1.01) 0.69 (0.52-0.90) 
 
Note. PWID=people who inject drugs; NK=not known. 
†Radiology includes ultrasound and Fibroscan. Other/NK includes biopsy, LFTs and 
platelets, hyaluronic acid, endoscopy, and NK.  
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Table 3. Results of Cox regression analysis to estimate the unadjusted and adjusted hazard ratios 
(HR) of variceal bleeding associated with period;the  study population is defined as all patients 
with date of cirrhosis diagnosis between 1 January 2005 and 31 December 2016 (N=2740).   
 
  Follow-up Rate per Unadjusted Adjusted  
Covariate n (yrs) 1000 p-yrs HR  (95% CI) HR  (95% CI) 
 
(All) 88 9406 9.4 -  - 
 
Male 67 6988 9.6 Ref.  - 
Female 21 2417 8.7 0.90 (0.55-1.47) - 
 
Age 
 <40 15 1298 11.6 1.24 (0.67-2.28) - 
 40-59 34 3715 9.2 Ref.  - 
 50-59 24 3080 7.8 0.89 (0.52-1.50) -  
 60+ 15 1312 11.4 1.36 (0.74-2.52) - 
 
Period 
 2005-2007 7 341 20.6 1.81 (0.71-4.60) 1.64 (0.64-4.22) 
 2008-2010 13 1086 12.0 Ref.  Ref. 
 2011-2013 20 2815 7.1 0.64 (0.32-1.29) 0.76 (0.37-1.55) 
 2014-2016 48 5164 9.3 0.87 (0.47-1.63) 1.25 (0.65-2.42) 
 
Alcohol use history 
 >50 units/wk 44 3659 12.0 Ref.  Ref. 
 ≤50 units/wk 44 5746 7.7 0.63 (0.41-0.95) 0.76 (0.50-1.18) 
  or NK 
 
Mode of cirrhosis diagnosis 
 Radiology† 63 7005 9.0 Ref.  Ref. 
 Clinical exam. 11 688 16.0 1.85 (0.97-3.51) 1.00 (0.50-1.99) 
 Other/NK† 14 1713 8.2 1.02 (0.57-1.84) 1.07 (0.57-1.98) 
  
Antiviral therapy/outcome 
 Never treated 60 5190 11.6 1.06 (0.55-2.05)  
 Treated/non-SVR 11 1077 10.2 Ref.  Ref. 
 Treated/SVR 17 3138 5.4 0.54 (0.25-1.16) 0.56 (0.32-0.97) 
 
Ascites 
 No 59 8157 7.2 Ref.  Ref. 
 Yes 29 1249 23.2 3.33 (2.13-5.20) 2.95 (1.79-4.86) 
 
Encephalopahy 
 No 82 9008 9.1 Ref.  - 
 Yes 6 398 15.1 1.65 (0.72-3.78) - 
 
 
Note. Age, ascites, encephalopathy, antiviral treatment outcome, and antiviral 
therapy/outcome all defined as time-dependent covariates.   
†Radiology includes ultrasound and Fibroscan. Other/NK includes biopsy, LFTs and 
platelets, hyaluronic acid, endoscopy, and NK. 
*Reference category for adjusted analysis is aggregate of Never treated and Treated/non-
SVR categories, as univariate analysis indicated a HR near 1.0.  
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FIGURE LEGEND 
Fig. 1. Upper panel: annual number of patients endoscopically screened among population of 
chronic HCV-infected patients diagnosed with cirrhosis between 1 January 2005 and 31 December 
2016 (screened within 12 months prior to or at any time after cirrhosis diagnosis). This panel also 
shows the annual number of  first admissions for bleeding varices following cirrhosis diagnosis in 
the same study population. Lower panel: annual proportion of newly diagnosed cirrhotic patients 
screened within 12 months prior to or following diagnosis date, with 95% confidence band.
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